Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic.

Aim: To assess the overall satisfaction level of movement disorder specialists using a virtual platform during the COVID-19 pandemic. Methods: This was a multicenter cross-sectional survey for a 6-month period during the beginning of the COVID-19 pandemic. Movement disorder specialists, who utilized telehealth visits from March 2020 to August 2020, were included. The study surveys, including provider's satisfaction with the care that they were able to provide and visit quality, were completed by the provider after each visit. Results: A total of 206 visits, provided by movement disorder specialists, were analyzed. Zoom was the most popular platform used for remote visits (70, 34%). A backup platform was not needed in the majority of movement disorder visits (171, 83%). The majority of physicians were very satisfied or satisfied with the care provided (72.9%) and visit quality (61%). Conclusions: The satisfaction level of specialists using telemedicine during COVID-19 was high despite having encounters with elderly patients with cognitive impairment or lacking advanced skills with technology.

Sialorrhea in Parkinson's Disease.

Sialorrhea, or excessive saliva beyond the margin of the lip, is a common problem in many neurological diseases. Previously, sialorrhea has been underrecognized in Parkinson's disease (PD) patients. Despite this, many patients rank sialorrhea as one of the most debilitating complaints of Parkinson's disease. Previous treatment for sialorrhea has been suboptimal and has been plagued by significant side effects that are bothersome and can be dangerous in patients with a concurrent neurodegenerative disease. This review sought to review the anatomy, function, and etiology of sialorrhea in PD. It then sought to examine the evidence for the different treatments of sialorrhea in PD, and further examined newer evidence for safety and efficacy in minimally invasive treatment such as botulinum toxin.

Analytical Evaluation Of Drug Package Inserts

Introduction: Package inserts are officially approved documents accompanying the drug which intends to provide information on safety and effectiveness of the product. This information is in accordance to country specific regulatory guidelines. It serves as a source of information to both users and prescribers. Hence the information incorporated has to be optimal to avoid medication errors.Objectives: Evaluate the package inserts for completeness of information according to heading mentioned in Section 6.2 and 6.3 of schedule D of Drug and Cosmetic Rule, 1945.Methods: Package inserts were collected from five pharmacies on request over a duration of 1 month and were analysed for the completeness of information according to Section 6.2 and 6.3 of schedule D of Drug and Cosmetic Rule, 1945. Information if present under the defined header, was scored one and zero if not. Total score ofeach header was calculated by adding the score from the individual package insert.Results: 80 package inserts were included in the study. None of the reviewed package inserts contained all the headers as required by the Drugs and Cosmetics Act. Total 16 headings were evaluated under both Section 6.2 and 6.3, highest value for the presence of heading were 15 out of 16 headers. That shows the best value of compliance was 93.75%.Conclusion: Present study encountered incompleteness of information in the package inserts. It is, therefore recommended that regulatory body should strengthen rules and regulations for the pharmaceutical companies to increase the compliance of adequacy of information in their package inserts to ensure rationale, effective and safe use of medicines